Acabrunat 100 mg Capsule

Acabrunat 100 mg Capsule (Acalabrutinib 100 mg) – Generic Alternative to Calquence

Acabrunat 100 mg Capsule is a prescription Bruton’s tyrosine kinase (BTK) inhibitor indicated for the treatment of selected hematologic malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). It contains Acalabrutinib 100 mg, the same active pharmaceutical ingredient as Calquence, the originator brand developed by AstraZeneca. Acalabrutinib is a next-generation targeted therapy that has become a cornerstone in the management of several B-cell malignancies across the United States, United Kingdom, Europe, Canada, and Australia.

Product Information

• Generic Name: Acalabrutinib 100 mg
• Drug Class: Bruton’s Tyrosine Kinase (BTK) Inhibitor
• Brand Reference: Calquence (AstraZeneca)
• Indication: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL)
• Standard Dose: Typically 100 mg twice daily or as prescribed by an oncologist or hematologist.
• Form: Capsule
• Route: Oral
• Prescription: Yes
• Evidence: FDA-, EMA-, and MHRA-approved indications. Supported by pivotal ELEVATE-TN, ASCEND, and ELEVATE-RR clinical trials demonstrating significant efficacy in B-cell malignancies.

Acalabrutinib works by selectively inhibiting Bruton’s tyrosine kinase (BTK), an enzyme essential for the growth, proliferation, and survival of malignant B cells. By blocking BTK signaling pathways, Acabrunat helps slow disease progression and promotes cancer cell death while minimizing off-target effects associated with earlier BTK inhibitors. This targeted mechanism has significantly improved treatment outcomes in patients with hematologic cancers.

Acabrunat 100 mg Capsule is commonly prescribed for adults with newly diagnosed or relapsed/refractory CLL, SLL, and MCL. It is frequently considered as part of long-term treatment strategies and may be administered alone or in combination with other therapies based on individual patient characteristics and disease status. Regular monitoring of blood counts, liver function, and cardiovascular health may be recommended during treatment.

Patients searching for Acabrunat 100 mg Capsule, Acalabrutinib 100 mg, generic alternative to Calquence, BTK inhibitor, CLL treatment, SLL medication, mantle cell lymphoma therapy, or targeted blood cancer treatment are referring to the same active ingredient. While Calquence remains the most recognized originator brand globally, generic Acalabrutinib products continue to expand access to advanced oncology therapies in international markets.

Buy Acabrunat 100 mg Capsules online from a trusted pharmaceutical supplier offering genuine oncology medicines, competitive pricing, secure ordering, and worldwide shipping where permitted by local regulations. Oncology medicines should only be used under specialist supervision, with individualized treatment planning and ongoing monitoring throughout therapy.

Frequently Asked Questions

What is Acabrunat 100 mg Capsule used for?

Acabrunat 100 mg Capsule is used for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL).

Is Acabrunat the same as Calquence?

Acabrunat contains Acalabrutinib, the same active ingredient found in Calquence. Calquence is the originator brand developed by AstraZeneca.

How does Acalabrutinib work?

Acalabrutinib blocks Bruton’s tyrosine kinase (BTK), helping prevent the growth and survival of malignant B cells.

What are the common side effects of Acalabrutinib?

Common side effects include headache, diarrhea, fatigue, upper respiratory tract infections, bruising, anemia, and reduced blood cell counts.

Is Acalabrutinib chemotherapy?

No. Acalabrutinib is a targeted therapy (BTK inhibitor) and is not considered traditional chemotherapy.

Can Acalabrutinib be taken with food?

Yes. Acabrunat may generally be taken with or without food, according to prescribing instructions from the treating physician.